Children born deaf now dancing to music after ‘astounding’ treatment

A treatment for a common form of hereditary deafness is a success (Picture: Getty/Tetra images RF)

Two children in China who were born deaf can now listen and dance to music after undergoing pioneering gene therapy that restored hearing in both ears.

They are among a small group of patients who were the first in the world to receive this ground-breaking treatment.

Given as an infusion into the ear, it works by replacing the faulty DNA which causes a type of inherited deafness known as DFNB9.

Five children – two girls and three boys – gained hearing abilities in both ears, and were able to hear and speak words and locate where a sound was coming from.

But two of them showed more advanced improvements and were able to respond to music, which has more complex sound signals, the researchers said.

Zheng-Yi Chen, an associate scientist in the Eaton-Peabody Laboratories at Mass Eye and Ear in the US, said: ‘The results from these studies are astounding.

Dr Yilai Shu examines one of the patients (Picture: Eye & ENT Hospital of Fudan University/PA)

‘We continue to see the hearing ability of treated children dramatically progress and the new study shows added benefits of the gene therapy when administrated to both ears.’

The team said treating children in both ears gives them the ability to hear sound in three dimensions, which is important for communication and common daily tasks such as driving.

The researchers said their work, published in the journal Nature Medicine, shows this type of treatment ‘holds great promise and warrants larger international trials’.

While this experimental therapy targets only one condition, the hope is that similar treatments could in future help many more children with other types of deafness caused by genes.

The latest results build on the work the team did two years ago, when they treated children in one ear.

After the gene therapy, the children went from being profoundly deaf to having mild to moderate hearing loss in the treated ear.

Five children received treatment (Picture: Eye & ENT Hospital of Fudan University/PA)

But administering the therapy in both ears reaped additional benefits compared with the previous trial, the team said, including being able to hear in noisy environments.

DFNB9 is one of the most common forms of hereditary deafness.

There are thought to be 20,000 people in Europe and the US with the condition.

It is caused by a failure to produce a protein known as otoferlin, which is necessary for the transmission of the sound signals from the ear to the brain.

Currently, a cochlear implant is the only effective treatment recommended to DFNB9 patients.

DFNB9 is typically treated using a cochlear implant (Picture: Getty)

To deliver the treatment, the researchers used a modified version of the adeno-associated virus (AAV), which is not harmful to humans.

The AAV was tweaked by the scientists so it could carry a version of the human OTOF gene, and given as an infusion into the inner ears of the patients.

The children were observed for 13 weeks or 26 weeks at the Eye & ENT Hospital of Fudan University in Shanghai, China.

The researchers said that no major side effects were seen and the trial remains ongoing where the patients are continuing to be monitored.

They also added that further work is needed to refine the therapy.

To view this video please enable JavaScript, and consider upgrading to a web
browser that
supports HTML5
video

Up Next

The results come after a girl in the UK also received a similar type of gene therapy in a separate clinical trial at Addenbrooke’s Hospital in Cambridge.

Opal Sandy, 18 months, from Oxfordshire, had the treatment in her right ear under general anaesthetic, and a cochlear implant was put into her left ear.

Just a few weeks later, she could hear loud sounds, such as clapping.

Now six months after treatment, she is able to hear soft sounds, such as a whisper, and is starting say words such as ‘mama’, ‘dada’ and ‘uh oh’.

Leave a Reply

Your email address will not be published. Required fields are marked *